Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors

Cancer Cell International

Xing-ya Li²  Li-juan Chen³  Jie Liu³  Xiu-feng Hu³  Shu-jing Shen²  Rui-qing Liu¹ 

[1] He Nan Provincial people's Hospital/Affiliated People's Hospital of Zhengzhou University, Zhengzhou 450003, China;First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China;He Nan Province Tumor hospital/Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, China

关键词: Prognosis;    Survival;    Adjuvant chemotherapy;    Hepatitis B virus;    Intrahepatic cholangiocarcinoma;   

Others  :  792805
DOI  :  10.1186/1475-2867-13-99

 received in 2013-01-22, accepted in 2013-10-11,  发布年份 2013

【 摘 要 】

Aim

The incidence and mortality associated with intrahepatic cholangiocarcinoma is increasing in many countries and documentation of disease outcome is sparse. The present study was undertaken to investigate the prognostic factors for intrahepatic cholangiocarcinoma (ICC) following surgical resection. The impact of pre-existing HBV virus infection and adjuvant chemotherapy on the overall survival was also evaluated.

Methods

Clinical and pathological data were collected retrospectively from 81 patients undergoing surgery for ICC between 2005 and 2011, at The Henan Province Tumor Hospital and the First Affiliated Hospital of Zheng Zhou University. Survival and prognosis were analyzed using the Kaplan-Meier method and COX regression model.

Results

The population included 37 patients who were HBsAg + or anti-HBc+, 21 patients who were anti-HBs + positive and 18 patients who received adjuvant chemotherapy. The overall 1- and 3-year survival rates were 51% and 20%, respectively. The median survival was 12.2 months. Univariate analysis identified the following prognostic factors: HBV virus infection or HBV vaccine prior to resection (P = 0.017); adjuvant chemotherapy (P = 0.001); preoperative serum CA19-9 (> 200 U/mL; P = 0.015); GGT (> 64 U/L; P = 0.008), ALP (> 119 U/L; P = 0.01); lymph node metastasis (P = 0.005); radical resection (P = 0.021); intrahepatic metastasis (P = 0.015) and diabetes (P = 0.07). Multivariate analysis identified chronic HBV infection (RR = 0.583; P = 0.041), anti-HBs positivity (RR = 0.680; P = 0.050), adjuvant chemotherapy (RR = 0.227; P < 0.001), lymph node metastasis (RR = 2.320; P = 0.001), and intrahepatic duct stones (RR = 0.473; P = 0.032) as independent prognostic factors.

Conclusions

HBV virus infection or HBV vaccination prior to resection, together with adjuvant chemotherapy, were independently associated with improved survival in patients undergoing surgery for ICC.

【 授权许可】

   
2013 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Ikai I, Itai Y, Okita K, et al.: Report of the 15th follow-up survey of primary liver cancer. Hepatol Res 2004, 28(1):21-29.
• [2]Khan SA, Thomas HC, Davidson BR, et al.: Cholangiocarcinoma. Lancet 2005, 366(9493):1303-1310.
• [3]Wang W-l, Guang-yu G, Min H: Expressionandsignificance of hepatitis Bvirus genes inhumanprimaryintrahepatic cholangiocar-cinomaanditssurroundingtissue. Chin J Oncol 1996, 18(2):127-129.
• [4]Qu ZL, Zou SQ, Cui NQ, et al.: Upregulation of human telomerase reverse transcriptase mRNA expression by in vitrotransfection of hepatitis B virus X gene into human hepatocarcinoma and cholangiocarcinoma cells. World J Gastroenterol 2005, 11(36):5627-5632.
• [5]Zhang L, Cai JQ, Zhao JJ, et al.: Impact of hepatitis B virus infection on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol 2010, 101(3):233-238.
• [6]Zhou HB, Wang H, Li YQ, et al.: Hepatitis B virus infection: A favorable prognostic factor for intrahepatic cholangiocarcinoma after resection. World J Gastroenterol 2011, 17(10):1292-1303.
• [7]Vitale F, Tramuto F, Orlando A, et al.: Can the serological status of anti-HBc alone be considered a sentinel marker for detection of occult HBV infection. J Med Virol 2008, 80(4):577-582.
• [8]Arase Y, Suzuki F, Suzuki Y, et al.: Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance. Intervirology 2007, 50(3):161-165.
• [9]Thongprasert S: The role of chemotherapy in cholangiocarcinoma. Ann Oncol 2005, 16(2):ii93-ii96.
• [10]Yue M, Ying-Chun X, Lei T, et al.: Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol & Oncol 2012, 1:11. BioMed Central Full Text
• [11]Chen LP, Li C, Wang C, et al.: Predictive factors of recurrence for patients with intrahepatic cholangiocarcinoma after hepatectomy. Hepatogastroenterology 2012, 59(118):1765-1768.
• [12]Nanashima A, Sumida Y, Abo T, et al.: Relationship between pattern of tumor enhancement and clinicopathologic characteristics in intrahepatic cholangiocarcinoma. J Surg Oncol 2008, 98(7):535-539.
• [13]Haruna Y, Saito K, Spaulding S, et al.: Identification of bipotential progenitor cells in human liver development. Hepatology 1996, 23(3):476-481.
• [14]Ding F-x, Wang F, Yi-ming L, et al.: Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus–related hepatocellular carcinoma. Hepatology 2009, 49(5):1492-1502.
• [15]Morise Z, Sugioka A, Tokoro T, et al.: Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol 2010, 2(2):58-64.
• [16]Li F-H, Chen X-Q, Luo Y-H, et al.: Prognosis of 84 intrahepatic cholangiocarcinoam patients. Chin J Cancer 2009, 28(5):528-532.
• [17]Jan YY, Yeh CN, Yeh TS, et al.: Prognostic analysis of surgical treatment of periheral cholangiocarcinoma: two decades of experience at chang gung memorial hospital. World J Gas-troenterol 2005, 11(12):1779-1784.
• [18]Patel AH, Harnois DM, Klee GG, et al.: The utility of CA 19–9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000, 95(1):204-207.
• [19]Ohtsuka M, Ito H, Kimura F, et al.: Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg 2002, 89(12):1525-1531.
• [20]Cho SY, Park SJ, Kim SH, et al.: Survival analysis of intrahepatic cholangiocarcinoam after resection. Ann Surg Oncol 2010, 17(7):1823-1830.
• [21]Nathan H, Aloia TA, Vauthey J-N, et al.: A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009, 16(1):14-22.
• [22]Uenishi T, Yamazaki O, Yamamoto T, et al.: Serosal invasion in TNM staging of mass-forming intrahepatic cholangiocarcinoma. Hepatobiliary Pancreat Surg 2005, 12(6):479-483.
• [23]Li HY, Zhou SJ, Li M, et al.: Diagnosis and cure experience of hepatolithiasis- associated intrahepatic cholangiocarcinoma in 66 patients. Asian Pac J Cancer Prev 2012, 13(2):725-729.
• [24]Zhao S-b, Cai-de L: Dignosis and treatment hepatolithias associated with cholangiocarcinoma:a report of 28 cases. Int J Surg 2010, 7(37):445-447.
• [25]Chun-xing L, Zhou J: Association between diabetes mellitus and the risk of extrahepatic cholangiocarcinoma: a Meta-analysis. Actauniversitats Medicinalis Nedicinalis Nanjing (Natural Science) 2011, 6(31):834-837.